3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Advanced Breast Cancer
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
Nivolumab
4
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Sigmoidoscopy
2
Proctoscopy
2
Colonoscopy
2
Biopsy
2
trastuzumab deruxtecan
1
dehydroftorafur
1
X-Rays
1
Watchful Waiting
1
Tomography, X-Ray Computed
1
Taxes
1
Surveys and Questionnaires
1
Sentinel Lymph Node Biopsy
1
Radiotherapy, Intensity-Modulated
1
Radionuclide Imaging
1
Phantoms, Imaging
1
Paclitaxel
1
Observation
1
Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin
1
Mitozytrex
1
Mitomycin
1
Magnetic Resonance Imaging
1
Ipilimumab
1
Ibuprofen
1
Fluorouracil
1
Fluorodeoxyglucose F18
1
Epinephrine
1
Electrocardiography
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled